Editas Medicine Inc. Common Stock (EDIT)
Stock · NASDAQ · Health Care
$2.36as of 10/16/2026
Price chart
Active signals
Resistance level
$2.71
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDIT Signal Track Record
How signals performed across all stocks →What EDIT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -9.1% | 34% | September 16, 2026 |
| Bollinger Band Breakout | 27 | -8.5% | 41% | August 19, 2026 |
| Bollinger Band Breakdown | 17 | -6.9% | 35% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +5.3% | 50% | October 2, 2026 |
| Any 20-session window (baseline) | -4.2% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develop…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 87
- Website
- www.editasmedicine.com/
Fundamentals
- 1-day range
- $2.25$2.47
- Market cap
- $283.93M
- P/E (trailing)
- —
- P/E (forward)
- -3.24
- EPS (trailing)
- $-0.74
- Dividend yield
- —
- Beta
- 2.13
- Avg. volume
- 2.52M
52-week range
$1.66$4.33
Next earnings: November 9, 2026 · EPS estimate $-0.21confirmed
Forecasts
10 analyst ratings
Buy 67%
Hold 22%
Sell 11%
1-year price forecast
High
$15
+535.6%
Median
$5.5
+133.1%
Low
$1
-57.6%
Editas Medicine Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- SRZNSurrozen Inc. Common Stock$23.44▼ 6.50%Market cap $251.25MP/E —$11.39$37.83
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| SRZN Surrozen Inc. Common Stock | $251.25M | — | $23.44 | ▼ 6.50% | $11.39$37.83 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Is Vertex Stock Worth More Than Its Competitors?Yahoo · 10/9/2026
- EDIT Set to Begin First-in-Human Study in HypercholesterolemiaYahoo · 10/9/2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo · 10/8/2026
- Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027Yahoo · 10/8/2026
- Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6benzinga · 10/8/2026
- Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6Benzinga · 10/8/2026
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with HyperlipidemiaYahoo · 10/8/2026
- Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In AustraliaBenzinga · 10/8/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
Insider Activity
Insider Actions →Acquired
1.31M
Disposed
28.5K
- Ory Daniel Scott · September 8, 2026 · Grant950.0K
- Amy Parison · September 3, 2026 · Sale453 @ $3.04
- Linda Burkly · September 3, 2026 · Sale709 @ $3.04
- Gilmore Neil O'Neill · September 3, 2026 · Sale5.1K @ $3.04
- Ellinor Patrick Thomas II · August 6, 2026 · Grant103.4K
- Amy Parison · August 3, 2026 · Sale678 @ $2.58
- Linda Burkly · July 28, 2026 · Sale4.9K @ $2.67
- Bernadette Connaughton · June 17, 2026 · Grant51.7K
- Scadden David · June 17, 2026 · Grant51.7K
- Levy Elliott M. · June 17, 2026 · Grant51.7K
- Jessica Hopfield · June 17, 2026 · Grant51.7K
- Andrew Hirsch · June 17, 2026 · Grant51.7K
- Amy Parison · June 3, 2026 · Sale464 @ $2.7
- Gilmore Neil O'Neill · June 3, 2026 · Sale15.4K @ $2.7
- Linda Burkly · June 3, 2026 · Sale731 @ $2.7
Institutional Ownership
March 31, 2026
- Total shares held
- 46.71M
- Total value held
- $109.73M
- Institutional holders
- 203
Top holders this quarter
- Unknown9.26M
- Unknown4.20M
- Unknown3.97M
- Unknown2.31M
- Unknown2.08M
- Unknown1.98M
- Unknown1.94M
- Unknown1.93M
- Unknown1.55M
- Unknown1.46M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.